Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: post-hoc analysis of the Kremezin Study against renal disease progression in Korea [Volume 36, Issue 1, March 2017, Pages 68–78]

Article information

Kidney Res Clin Pract. 2018;37(1):98-99

Publication date (electronic) : 2018 March 31

doi : https://doi.org/10.23876/j.krcp.2018.37.1.98

¹Department of Internal Medicine, National Medical Center, Seoul, Korea

²Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

³Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea

⁴Department of Internal Medicine, Korea University Ansan-Hospital, Korea University College of Medicine, Seoul, Korea

⁵Department of Internal Medicine, Seoul National University Bundang Hopsital, Seongnam, Korea

⁶Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

⁷Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea

⁸Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Uijeongbu, Korea

⁹Department of Internal Medicine, Inje University Ilsan-Paik Hospital, Goyang, Korea

¹⁰Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea

¹¹Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University of Medicine and Science, Incheon, Korea

¹²Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea

¹³Kidney Research Institute, Seoul National University, Seoul, Korea

Correspondence: Yon Su Kim, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea. E-mail: yonsukim@snu.ac.kr. ORCID: http://orcid.org/0000-0003-3091-2388

The above article (https://doi.org/10.23876/j.krcp.2017.36.1.68) contains errors.

The values of y axis in Fig. 3 should be corrected as following page.

Figure 3

Change of estimated glomerular filtration rate (eGFR) over time

(A) From whole per-protocol participants (P_{randomization} = 0.18, P_{randomization-time} = 0.04). (B) From participants without a composite primary outcome (P_{randomization} = 0.01). (C) From participants with a composite primary outcome (P_{randomization} = 0.28). (D) From participants with diabetic nephropathy (P_{randomization} = 0.54, P_{randomization-time} = 0.049). (E) From participants with non-diabetic nephropathy (P_{randomization} = 0.21).

The authors would like to apologize for any inconvenience this has caused.

Article information Continued

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.